Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation

Ziyuglycoside II (ZGS II) is a major bioactive ingredient of Sanguisorbae officinalis L., which has been widely used for managing myelosuppression or leukopenia induced by chemotherapy or radiotherapy. In the current study, we investigated the pro-hematopoietic effects and underlying mechanisms of Z...

Full description

Bibliographic Details
Main Authors: Haihong Fang, Xinxu Xie, Peng Liu, Ying Rao, Yaru Cui, Shilin Yang, Jun Yu, Yingying Luo, Yulin Feng
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332220310544
id doaj-22c66dbed3984c0dafbf5d9b0d815f8d
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Haihong Fang
Xinxu Xie
Peng Liu
Ying Rao
Yaru Cui
Shilin Yang
Jun Yu
Yingying Luo
Yulin Feng
spellingShingle Haihong Fang
Xinxu Xie
Peng Liu
Ying Rao
Yaru Cui
Shilin Yang
Jun Yu
Yingying Luo
Yulin Feng
Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation
Biomedicine & Pharmacotherapy
Ziyuglycoside II
Leukopenia
Hematopoietic stem and progenitor cells
Proliferation
RNA-seq
author_facet Haihong Fang
Xinxu Xie
Peng Liu
Ying Rao
Yaru Cui
Shilin Yang
Jun Yu
Yingying Luo
Yulin Feng
author_sort Haihong Fang
title Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation
title_short Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation
title_full Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation
title_fullStr Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation
title_full_unstemmed Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation
title_sort ziyuglycoside ii alleviates cyclophosphamide-induced leukopenia in mice via regulation of hspc proliferation and differentiation
publisher Elsevier
series Biomedicine & Pharmacotherapy
issn 0753-3322
publishDate 2020-12-01
description Ziyuglycoside II (ZGS II) is a major bioactive ingredient of Sanguisorbae officinalis L., which has been widely used for managing myelosuppression or leukopenia induced by chemotherapy or radiotherapy. In the current study, we investigated the pro-hematopoietic effects and underlying mechanisms of ZGS II in cyclophosphamide-induced leukopenia in mice. The results showed that ZGS II significantly increased the number of total white blood cells and neutrophils in the peripheral blood. Flow cytometry analysis also showed a significant increase in the number of nucleated cells and hematopoietic stem and progenitor cells (HSPCs) including ST-HSCs, MPPs, and GMPs, and enhanced HSPC proliferation in ZGS II treated mice. The RNA-sequencing analysis demonstrated that ZGS II effectively regulated cell differentiation, immune system processes, and hematopoietic system-related pathways related to extracellular matrix (ECM)-receptor interaction, focal adhesion, hematopoietic cell lineage, cytokine-cytokine receptor interaction, the NOD-like receptor signaling pathway, and the osteoclast differentiation pathway. Moreover, ZGS II treatment altered the differentially expressed genes (DEGs) with known functions in HSPC differentiation and mobilization (Cxcl12, Col1a2, and Sparc) and the surface markers of neutrophilic precursors or neutrophils (Ngp and CD177). Collectively, these data suggest that ZGS II protected against chemotherapy-induced leukopenia by regulating HSPC proliferation and differentiation.
topic Ziyuglycoside II
Leukopenia
Hematopoietic stem and progenitor cells
Proliferation
RNA-seq
url http://www.sciencedirect.com/science/article/pii/S0753332220310544
work_keys_str_mv AT haihongfang ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation
AT xinxuxie ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation
AT pengliu ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation
AT yingrao ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation
AT yarucui ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation
AT shilinyang ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation
AT junyu ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation
AT yingyingluo ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation
AT yulinfeng ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation
_version_ 1721432839252082688
spelling doaj-22c66dbed3984c0dafbf5d9b0d815f8d2021-05-21T04:18:31ZengElsevierBiomedicine & Pharmacotherapy0753-33222020-12-01132110862Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiationHaihong Fang0Xinxu Xie1Peng Liu2Ying Rao3Yaru Cui4Shilin Yang5Jun Yu6Yingying Luo7Yulin Feng8State Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China; School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, ChinaState Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, ChinaState Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, ChinaState Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, ChinaState Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, ChinaState Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China; National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herb Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, ChinaDepartment of Physiology and Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA19140, USAState Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China; National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herb Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China; Corresponding author.State Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China; National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herb Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China; Corresponding author at: No. 56 Yangming Road, Donghu District, Nanchang City, Jiangxi University of Traditional Chinese Medicine, 330006, China.Ziyuglycoside II (ZGS II) is a major bioactive ingredient of Sanguisorbae officinalis L., which has been widely used for managing myelosuppression or leukopenia induced by chemotherapy or radiotherapy. In the current study, we investigated the pro-hematopoietic effects and underlying mechanisms of ZGS II in cyclophosphamide-induced leukopenia in mice. The results showed that ZGS II significantly increased the number of total white blood cells and neutrophils in the peripheral blood. Flow cytometry analysis also showed a significant increase in the number of nucleated cells and hematopoietic stem and progenitor cells (HSPCs) including ST-HSCs, MPPs, and GMPs, and enhanced HSPC proliferation in ZGS II treated mice. The RNA-sequencing analysis demonstrated that ZGS II effectively regulated cell differentiation, immune system processes, and hematopoietic system-related pathways related to extracellular matrix (ECM)-receptor interaction, focal adhesion, hematopoietic cell lineage, cytokine-cytokine receptor interaction, the NOD-like receptor signaling pathway, and the osteoclast differentiation pathway. Moreover, ZGS II treatment altered the differentially expressed genes (DEGs) with known functions in HSPC differentiation and mobilization (Cxcl12, Col1a2, and Sparc) and the surface markers of neutrophilic precursors or neutrophils (Ngp and CD177). Collectively, these data suggest that ZGS II protected against chemotherapy-induced leukopenia by regulating HSPC proliferation and differentiation.http://www.sciencedirect.com/science/article/pii/S0753332220310544Ziyuglycoside IILeukopeniaHematopoietic stem and progenitor cellsProliferationRNA-seq